Abelson, MD, and ORA Clinical Research & Development North Andover, Mass. The 2006 Association for Research in Vision and Ophthalmology annual meeting in Ft. Lauderdale, Fla., upheld its reputation, yet again, as the ultimate forum for ophthalmic research. A record-breaking 10,200 participants were present this year. The amazing quantity of fields covered and research results presented made the week a busy one for all who attended. As it is virtually impossible to canvass the vast expanses of research presented each day, we hope this summation of some interesting highlights will prove useful both for those who could not attend as well as those who did visit this year's ARVO meeting.
Anti-Infectives and Anti-Inflammatories The anti-infective arena saw Phase III results presented from an active-controlled azithromycin clinical trial. In this study, InSite's 1% azithromycin ophthalmic solution (AzaSite) dosed b.i.d. For the first two days and q.d. For days three to five was equivalent to tobramycin 0.3% q.i.d.
Ufr ii canon. The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) is the largest gathering of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75. Video convertor for mac.
Ophthalmic solution in the treatment of bacterial conjunctivitis, using clinical cure and bacterial eradication as the clinical endpoints (Abelson MB, et al. IOVS 2006; 47:ARVO E-Abstract 3589).
The azithromycin ophthalmic solution represents an advance in the treatment of bacterial conjunctivitis, with its lower-frequency dosing schedule than currently available options such as tobramycin. Quickly and accurately identifying pathogens in corneal ulcers is often challenging. An advance that could help solve these problems was presented by researchers who showed that more rapid and accurate identification of pathogens from corneal ulcers can be achieved using a polymerase chain reaction (PCR) test (Qi et al. IOVS 2006; 47:ARVO E-Abstract 3582). In the study, a PCR test identified pathologic bacteria in two specimens that were negative in both smears and cultures. Similar results were obtained in a separate study of endophthalmitis specimens, which also identified positive specimens through PCR that were negative when cultured (Therese KL, et al.
IOVS 2006; 47: ARVO E-Abstract 1890). In the field of anti-inflammatory research, one study examined hydrocortisone 1% supplemented with anionic polar phospholipid (APP) cream compared with hydrocortisone 1% cream (Hytone) for the treatment of inflammatory eyelid disease. The hydrocortisone-supplemented APP cream showed 75 times greater penetration at four hours and 20 times greater penetration at eight hours. The APP vehicle may allow for a lower concentration of topical steroid to be dosed while still maintaining efficacy (Greiner, et al. IOVS 2006;47:ARVO E-Abstract 600). This formulation might become particularly useful in the long-term treatment of eyelid dermatoses where corticosteroids may be the appropriate treatment, but could be applied in lower dosages. Another advance in the arena of anti-inflammatory therapies was research presented on TNF-alpha inhibitors as potential treatments for posterior segment inflammatory disease.
Results presented from the Remicade European Study for Chronic Uveitis (RESCU) showed that infliximab (Remicade, Centocor) was generally well-tolerated and effective when used to treat uveitis (De Smet MD. IOVS 2006; 47:ARVO E-Abstract 1525).
Two other studies revealed similar findings, indicating that other TNF-alpha inhibitors, such as adalimumab, may also be effective in the treatment of posterior segment inflammatory disease (Rozenbaum I, et al. IOVS 2006;47:ARVO E-Abstract 2437; Zierhut M, et al. IOVS 2006; 47:ARVO E-Abstract 1526). Dry Eye Dry eye research presented at this year's ARVO included advances in diagnosing and categorizing, etiological aspects, and treating and managing dry eye. Many researchers acknowledge that tear-film breakup time (TFBUT), though widely used, remains a limited tool for diagnosis of dry-eye syndrome because it offers clues, but often an incomplete picture of the condition.
Changing the language of rhino from chinese to english. • You can only upload a photo (png, jpg, jpeg) or a video (3gp, 3gpp, mp4, mov, avi, mpg, mpeg, rm). • You can only upload a photo or a video.
The computer-driven Tear Stability Analysis System (TSAS) may help create a more holistic determination of tear-film stability. This system superimposes a color-coded topographical image over video of the ocular epithelium to determine the areas in which the tear film has parted.
It repeats this imaging process each second over a 10-second interval and calculates a breakup index (BUI), the value of which reflects the rapidity of breakup and the unprotected ocular surface area at each time point. While it is a more complete method of measuring tear-film stability, and may prove useful in research, TSAS uses highly advanced technology that could limit its potential as a basic diagnostic tool for everyday clinical use (Hara, S et al. IOVS 2006;47:ARVO E-Abstract 235). Tear-film breakup patterns (TFBUP), though not a replacement for breakup time measurements, also appear to have potential as a novel diagnostic tool. Five TFBUPs have been identified: linear; fractured; wispy; spotting; and amorphous blob. Each pattern may indicate a specific type or severity level of dry eye, and certain patterns are strongly correlated with longer or shorter TFBUTs.